


I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: April 11, 2005

Signature:

  
(Harvey L. Cohen)

Docket No.:  
SCHERING 3.0-122 CIP  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

  
In re Patent Application of:  
Anup Saksena

Application No.: 10/052,386

Group Art Unit: 1653

Filed: January 18, 2002

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE  
PROTEASE INHIBITORS OF  
HEPATITIS C VIRUS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT



Dear Sir:

It is respectfully requested that the reference listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of the patent abstract is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: April 11, 2005

Respectfully submitted,

  
By   
Harvey L. Cohen  
Registration No.: 28,365  
LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP  
600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorney for Applicant

04/14/2005 EAREGAY1 00000038 10052386

01 FC:1806 180.00 DA

LD-4581  
557003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 11, 2005

Signature:

(Harvey L. Cohen)

Docket No.:  
SCHERING 3.0-122 CIP  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 14 2005

In re Patent Application of:  
Anil Saksena

Application No.: 10/052,386

Group Art Unit: 1653

Filed: January 18, 2002

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE  
PROTEASE INHIBITORS OF HEPATITIS C  
VIRUS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the reference cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our deposit account No. 12-1095.

Dated: April 11, 2005

Respectfully submitted

By   
Harvey L. Cohen

Registration No.: 28,365  
LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP  
600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorney for Applicant

LD-453A

556999



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/052,386-Conf. #5995
				Filing Date	January 18, 2002
				First Named Inventor	Anil Saksena
				Art Unit	1653
				Examiner Name	R. B. Mondesi
Sheet	1	of	1	Attorney Docket Number	SCHERING 3.0-122 CIP

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
BA	JP-4-001140-A		01-06-1992	Microbial Chem	T <sup>6</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--